AQEMIA Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 85

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $7.4M

  • Investors
  • 14

AQEMIA General Information

Description

Developer of a drug discovery platform designed to discover new drugs for specific therapeutic targets. The company's platform combines machine learning and quantum-inspired statistical mechanics algorithms to generate lead-like molecules for a given target, enabling researchers to efficiently and accurately predict the affinity between drug candidates and therapeutic targets.

Contact Information

Website
www.aqemia.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1 Boulevard Pasteur
  • 75015 Paris
  • France
Primary Industry
Drug Discovery
Corporate Office
  • 1 Boulevard Pasteur
  • 75015 Paris
  • France

AQEMIA Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AQEMIA Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Grant 01-Apr-2025 $7.4M Completed Generating Revenue
12. Later Stage VC (Series A3) 10-Dec-2024 Completed Generating Revenue
11. Accelerator/Incubator 14-Jun-2023 Completed Generating Revenue
10. Accelerator/Incubator 01-Jan-2023 Completed Generating Revenue
9. Early Stage VC (Series A2) 19-Oct-2022 Completed Generating Revenue
8. Early Stage VC (Series A1) 02-May-2021 Completed Generating Revenue
7. Early Stage VC 10-Dec-2020 Completed Generating Revenue
6. Seed Round 17-Oct-2019 Completed Generating Revenue
5. Accelerator/Incubator 01-Jun-2019 Completed Generating Revenue
4. Accelerator/Incubator 01-Jan-2019 Completed Generating Revenue
To view AQEMIA’s complete valuation and funding history, request access »

AQEMIA Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
A2 Shares
A Shares
Ordinary 27,400 $0.010545 $2.69 $2.69 1x $2.69 1.09%
A Shares 333,500 $0.010545 $3.16 $3.16 1x $3.16 13.22%
To view AQEMIA’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

AQEMIA Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug discovery platform designed to discover new drugs for specific therapeutic targets. The company's pl
Drug Discovery
Paris, France
85 As of 2026

South San Francisco, CA
 

Oxford, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AQEMIA Competitors (9)

One of AQEMIA’s 9 competitors is insitro, a Venture Capital-Backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
insitro Venture Capital-Backed South San Francisco, CA
Exscientia Formerly VC-backed Oxford, United Kingdom
AbCellera Biologics Formerly VC-backed Vancouver, Canada
Ariana Pharma Formerly VC-backed Paris, France
Relay Therapeutics Formerly VC-backed Cambridge, MA
You’re viewing 5 of 9 competitors. Get the full list »

AQEMIA Patents

AQEMIA Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025252767-A1 3-(1h-indazol-3-yl)isoquinoline derivatives as map4k1 (hpk1) inhibitors and use thereof in therapy Pending 04-Jun-2024
JP-2026514449-A Novel mettl3 inhibitors and their therapeutic use Pending 30-Mar-2023
AU-2024244637-A1 Novel mettl3 inhibitors and use thereof in therapy Pending 30-Mar-2023
EP-4688768-A1 Novel mettl3 inhibitors and use thereof in therapy Pending 30-Mar-2023
WO-2024200835-A1 Novel mettl3 inhibitors and use thereof in therapy Inactive 30-Mar-2023 C07D401/14
To view AQEMIA’s complete patent history, request access »

AQEMIA Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AQEMIA Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cathay Capital PE/Buyout Minority
Cathay Innovation Venture Capital Minority
Idinvest Partners PE/Buyout Minority
Wendel Group Family Office Minority
La French Tech Accelerator/Incubator
You’re viewing 5 of 14 investors. Get the full list »

AQEMIA FAQs

  • When was AQEMIA founded?

    AQEMIA was founded in 2019.

  • Where is AQEMIA headquartered?

    AQEMIA is headquartered in Paris, France.

  • What is the size of AQEMIA?

    AQEMIA has 85 total employees.

  • What industry is AQEMIA in?

    AQEMIA’s primary industry is Drug Discovery.

  • Is AQEMIA a private or public company?

    AQEMIA is a Private company.

  • What is AQEMIA’s current revenue?

    The current revenue for AQEMIA is .

  • How much funding has AQEMIA raised over time?

    AQEMIA has raised $69.5M.

  • Who are AQEMIA’s investors?

    Cathay Capital, Cathay Innovation, Idinvest Partners, Wendel Group, and La French Tech are 5 of 14 investors who have invested in AQEMIA.

  • Who are AQEMIA’s competitors?

    insitro, Exscientia, AbCellera Biologics, Ariana Pharma, and Relay Therapeutics are some of the 9 competitors of AQEMIA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process